WCG acquires Trifecta Clinical to enhance clinical trial solutions and efficiency

In a significant move aimed at transforming the clinical trials landscape, WCG, a US-based clinical services company, has acquired Trifecta Clinical, a provider of technology-driven clinical trial solutions. Though the acquisition price remains undisclosed, this deal marks a pivotal moment in the ongoing evolution of clinical trial services. By integrating Trifecta’s innovative solutions into its own offerings, WCG aims to expand its range of specialized services and improve the overall efficiency of clinical research processes.

WCG’s acquisition of Trifecta Clinical is set to enhance the company’s existing services with Trifecta’s advanced site communication platform, InvestigatorSpace, alongside its virtual training programs and safety documentation services. These additions will bolster WCG’s ability to connect clinical research organizations (CROs), sponsors, and research sites, streamlining communication and operational workflows in clinical trials.

Donald A. Deieso, Executive Chairman and CEO of WCG, highlighted the strategic importance of this acquisition. According to Deieso, Trifecta’s comprehensive suite of services, which spans from regulatory document exchange to safety letter notifications, perfectly complements WCG’s existing value proposition. This expansion, he stated, is aligned with WCG’s broader strategy to deliver innovative solutions that anticipate the evolving needs of clinical trial participants, from sponsors to CROs.

The acquisition comes at a time when the clinical trials sector is experiencing rapid technological advancements aimed at improving efficiency and outcomes. With Trifecta Clinical now under WCG’s umbrella, the company is well-positioned to address long-standing challenges in the clinical trial ecosystem. WCG plans to leverage Trifecta’s expertise to not only enhance the efficiency of clinical trials but also improve the quality of research conducted across multiple sectors.

Dave Young, Founder and CEO of Trifecta Clinical, expressed excitement about the deal, noting that joining WCG would provide Trifecta with new opportunities to innovate further. “This acquisition was a natural evolution for Trifecta,” Young said. “We now have the resources and expertise of WCG behind us, enabling us to continue delivering impactful solutions and innovative approaches to our clients.”

Looking forward, Trifecta Clinical will continue to operate under the name WCG Trifecta. The company’s leadership structure remains unchanged, and its headquarters in Los Angeles, along with its other locations in Indianapolis, Philadelphia, and Osaka, Japan, will remain in place.

WCG’s strategic expansion into clinical trial services positions it as a leading force in the global research landscape. With this acquisition, the company is reinforcing its commitment to improving clinical trial efficiency, safety, and overall outcomes.